Register for free to
view the full innovation profile.
This technology is a 21-gene reactive oxygen species (ROS)-associated molecular signature that predicts survival in septic patients.
About
Reactive Oxygen Species Gene Signature Predicts Survival in Sepsis Tech ID: UA16-068 Invention: This technology is a 21-gene reactive oxygen species (ROS)-associated molecular signature that predicts survival in septic patients. This particular signature has outperformed randomly generated signatures of the same signature gene size. This signature is easily assayed from peripheral blood and can potentially predict. Background: There is a significant amount of evidence that oxidative stress plays a large role in pathogenesis of sepsis-associated multiple organ failure. Sepsis-related multiple organ dysfunction syndrome leads to a large number of deaths in intensive care units. Sepsis syndrome’s mortality rate is 26% to 82% depending on whether septic shock occurs. Currently, there are no reliable diagnostic biomarkers available to predict survival of patients with sepsis. Status: issued U.S. patent #11,230,735
Key Benefits
- Traditional biomarkers (C-reactive protein, interleukin-6, procalcitonin) are not reliable in predicting survival - ROS-associated biomarkers were shown to predict the odds of patient's outcome
Applications
- Diagnostic tool and/or service for patients with sepsis